Prosecution Insights
Last updated: November 04, 2026
Application No. 18/613,864

Windkessel Simulation Apparatus

Non-Final OA §102§103§DOUBLEPATENT
Filed
Mar 22, 2024
Examiner
KIPOUROS, HOLLY MICHAELA
Art Unit
1799
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Ventriflo Inc.
OA Round
1 (Non-Final)
70%
Grant Probability
Favorable
1-2
OA Rounds
4m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allowance Rate
381 granted / 544 resolved
+5.0% vs TC avg
Strong +21% interview lift
Without
With
+21.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
37 currently pending
Career history
579
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
49.8%
+9.8% vs TC avg
§102
19.9%
-20.1% vs TC avg
§112
24.9%
-15.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 544 resolved cases

Office Action

§102 §103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 1-13, in the reply filed on 10/12/2026 is acknowledged. Claims 14-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 10/12/2026. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 9 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Rinaldi et al. (US Patent Application Publication 2006/0236756). Regarding claim 1, Rinaldi et al. discloses a cardiovascular function simulation apparatus (Abstract, para. 14, claims 34-35) comprising: a flexible fluid container (called duct, element 10) having an exterior, a top, a bottom, and a set of ports (para. 38) (Figs. 1-2, sheets 1-2 of 5); wherein the flexible fluid container is configured to receive fluid through at least one port of the set of ports and to deliver fluid to a heart through at least one port of the set of ports (para. 2, 37-38, 110-112) (Figs. 1-2, sheets 1-2 of 5); and a reactive squeezing mechanism (comprising shell 12, cavities 14, and pump 4) configured to receive the flexible fluid container (para. 38) (Fig. 2, sheet 2 of 5) and to apply compressive pressure to its exterior in response to an increase in fluid within the flexible fluid container (para. 56-58, 67-70) (Figs. 1-4, sheets 1-2 of 5), such that the compressive pressure causes fluid to be driven toward the heart through at least one port of the set of ports (Abstract, para. 56-58, 67-70) (Figs. 1-4, sheets 1-2 of 5). Although Rinaldi et al. does not expressly use the term “Windkessel” when describing the simulation function of the apparatus, the prior art apparatus nonetheless reads on a “Windkessel simulation apparatus”, because Rinaldi et al. discloses wherein the apparatus is configured to simulate the flexible expansion and recoil of the aorta during the cardiac cycle (Abstract, para. 14-15, 110-111, claims 34-35), and this is synonymous with the Windkessel effect. Regarding claim 9, Rinaldi et al. discloses an ex vivo circulation system (Abstract, para. 2) having a flow path that includes a cardiovascular function simulation apparatus (Abstract, para. 14, claims 34-35) comprising: a flexible fluid container (called duct, element 10) having an exterior, a top, a bottom, and a set of ports (para. 38) (Figs. 1-2, sheets 1-2 of 5); wherein the flexible fluid container is configured to receive fluid through at least one port of the set of ports and to deliver fluid to a heart through at least one port of the set of ports (para. 2, 37-38, 110-112) (Figs. 1-2, sheets 1-2 of 5); and a reactive squeezing mechanism (comprising shell 12, cavities 14, and pump 4) configured to receive the flexible fluid container (para. 38) (Fig. 2, sheet 2 of 5) and to apply compressive pressure to its exterior in response to an increase in fluid within the flexible fluid container (para. 56-58, 67-70) (Figs. 1-4, sheets 1-2 of 5), such that the compressive pressure causes fluid to be driven toward the heart through at least one port of the set of ports (Abstract, para. 56-58, 67-70) (Figs. 1-4, sheets 1-2 of 5). Although Rinaldi et al. does not expressly use the term “Windkessel” when describing the simulation function of the apparatus, the prior art apparatus nonetheless reads on a “Windkessel simulation apparatus”, because Rinaldi et al. discloses wherein the apparatus is configured to simulate the flexible expansion and recoil of the aorta during the cardiac cycle (Abstract, para. 14-15, 110-111, claims 34-35), and this is synonymous with the Windkessel effect. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 8 is rejected under 35 U.S.C. 103 as being unpatentable over Rinaldi et al. (US Patent Application Publication 2006/0236756) in view of Kay et al. (US Patent Application Publication 2014/0377849). Regarding claim 8, Rinaldi et al. discloses the flexible fluid container, as set forth above. Rinaldi et al. is silent as to wherein the flexible fluid container further comprises an air elimination port oriented upwards such that it enables air to escape the flexible fluid container. Kay et al. discloses an ex vivo circulation system for perfusing an organ (Abstract) and further discloses that it is undesirable for air traps to form within the circulation system (para. 13). To this end, Kay et al. discloses providing a fluid duct with an air elimination port oriented upwards such that it enables air to escape the fluid duct (para. 12-13, 54). It would have been obvious to one of ordinary skill in the art at the time before the effective filing date of the claimed invention to modify the flexible fluid container disclosed by Rinaldi et al. to further comprise an air elimination port oriented upwards such that it enables air to escape the flexible fluid container, based on the teachings of Kay et al., in order to eliminate undesirable air pockets within the apparatus. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-2 and 6-10 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-2, 6-9, and 11 of copending Application No. 19086986 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because: Regarding claim 1, claim 1 of the reference application recites: A Windkessel simulation apparatus comprising: a flexible fluid container having an exterior, a top, a bottom, and a set of ports; wherein the flexible fluid container is configured to receive fluid through a first port of the set of ports (reads on at least one port of the set of ports) and to deliver fluid to a set of organs through a second port of the set of ports (reads on at least one port of the set of ports); a reactive squeezing mechanism configured to removably receive the flexible fluid container and to apply compressive pressure to its exterior in response to an increase in fluid within the flexible fluid container, such that the compressive pressure causes fluid to be driven toward the set of organs through the second port. Therefore, the only difference is that the reference application claim recites “a set of organs” rather than a heart. Nonetheless, this difference does not introduce a patentable distinction, because the heart is not a positively recited structural element of instant claim 1. The apparatus of the reference claim would be fully capable of delivering fluid to a heart. Regarding claim 2, claim 2 of the reference application recites the same subject matter. Regarding claim 6, claim 6 of the reference application recites the same subject matter. Regarding claim 7, claim 7 of the reference application recites the same subject matter. Regarding claim 8, claim 8 of the reference application recites the same subject matter. Regarding claim 9, claim 9 of the reference application recites the same subject matter. Regarding claim 10, claim 11 recites an ex vivo circulation system further comprising a main collection reservoir, a pump, an oxygenator, and an ex vivo container configured to hold an ex vivo heart (thus it is understood that the container would be fully capable of holding a heart having a right atrium, a right ventricle, a left atrium, and a left ventricle). As to the limitation of the container being a box, this is merely a recitation of the shape of the container and does not introduce a patentable distinction. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Allowable Subject Matter Claims 3-5 and 11-13 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Citation of Pertinent Prior Art The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Badiwala et al. (US Patent Application Publication 2020/0120924) is directed to an ex vivo circulation system for perfusing a heart, the system comprising a Windkessel element for storing and releasing elastic potential energy (para. 71). Pichotte et al. (US Patent Application Publication 2004/0026448) is directed to a perfusion device comprising a plate configured to compress a flexible bag. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to HOLLY KIPOUROS whose telephone number is (571)272-0658. The examiner can normally be reached M-F 8.30-5PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Marcheschi can be reached at 5712721374. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HOLLY KIPOUROS/Primary Examiner, Art Unit 1799
Read full office action

Prosecution Timeline

Mar 22, 2024
Application Filed
Oct 22, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781166
SMART TANK FOR A BIO-PHARMA PROCESS
3y 10m to grant Granted Nov 03, 2026
Patent 12779449
TRANSFER MECHANISM FOR TRANSFERRING OBJECTS THROUGH A TRANSFER PORT
3y 6m to grant Granted Nov 03, 2026
Patent 12742140
CULTURING SYSTEM AND METHOD FOR CULTURING CELLS
3y 8m to grant Granted Sep 22, 2026
Patent 12735665
GAS-PERMEABLE CONTAINER, AND CULTURE APPARATUS AND CULTURE SYSTEM EACH USING SAME
3y 4m to grant Granted Sep 15, 2026
Patent 12735670
SUPPORT STRUCTURES FOR AUTOMATED CELL ENGINEERING SYSTEMS
3y 7m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
70%
Grant Probability
91%
With Interview (+21.3%)
2y 11m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 544 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month